Скачать или смотреть 🌏 𝗨𝗦-𝗖𝗛𝗜𝗡𝗔 𝗕𝗜𝗢𝗣𝗛𝗔𝗥𝗠𝗔 𝗗𝗘𝗔𝗟𝗦: 𝗚𝗘𝗡𝗨𝗜𝗡𝗘 𝗥&𝗗 𝗘𝗫𝗣𝗔𝗡𝗦𝗜𝗢𝗡 𝗢𝗥 𝗜𝗡𝗡𝗢𝗩𝗔𝗧𝗜𝗢𝗡 𝗢𝗙𝗙𝗦𝗛𝗢𝗥𝗜𝗡𝗚?

🚀 How Will Regulatory Exclusivity Reshape Pharma? 🚀

The debate between regulatory exclusivity vs. patent exclusivity is heating up—especially for cell and gene therapies (CGTs). As the industry pivots towards regulatory-driven protections, what does this mean for innovation, pricing, and market competition?

🔹 Regulatory Exclusivity offers fixed-term market protection (e.g., 12 years for biologics, 7 years for orphan drugs).
🔹 Patent Exclusivity relies on legal protections but often faces litigation battles, delaying competition.

Key Predictions:
📈 R&D Shifts: Pharma will prioritize CGTs & biologics over small molecules to maximize exclusivity.

💰 Pricing Pressures: Extended exclusivity = prolonged high drug prices, impacting affordability.
⚖ Market Competition: Predictable entry for biosimilars & CGT alternatives, but manufacturing complexity may delay competitors.

📜 Regulatory Changes: Governments may reassess exclusivity terms to balance innovation with affordability.

Big Pharma Winners & Challenges:
🏆 Winners: Novartis, Gilead, BMS, Pfizer, and J&J—leaders in CGTs—stand to gain billions from extended exclusivity.
⚠ Challenges: Biosimilar-focused firms like Amgen & Biogen must adapt to shifting regulatory landscapes.

💡 Bottom Line: The future of drug exclusivity is changing. CGT-focused innovation will thrive, but balancing exclusivity with patient access remains a critical challenge.

💬 What are your thoughts? Should exclusivity policies evolve to support affordability while sustaining innovation? Let’s discuss it! 👇

#Pharma hashtag#Biotech hashtag#CellTherapy hashtag#GeneTherapy #RegulatoryAffairs #Innovation hashtag#DrugPricing hashtag#Healthcare